Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1076

1.

The effect of CYP4F2, VKORC1 and CYP2C9 in influencing coumarin dose. A single patient data meta-analysis in more than 15,000 individuals.

Danese E, Raimondi S, Montagnana M, Tagetti A, Langaee T, Borgiani P, Ciccacci C, Carcas AJ, Borobia AM, Tong HY, Dávila-Fajardo C, Botton MR, Bourgeois S, Deloukas P, Caldwell MD, Burmester JK, Berg RL, Cavallari LH, Drozda K, Huang M, Zhao LZ, Cen HJ, Gonzalez-Conejero R, Roldan V, Nakamura Y, Mushiroda T, Gong IY, Kim RB, Hirai K, Itoh K, Isaza C, Beltrán L, Jiménez-Varo E, Cañadas-Garre M, Giontella A, Kringen MK, Bente Foss Haug K, Gwak HS, Lee KE, Minuz P, Lee MTM, Lubitz SA, Scott S, Mazzaccara C, Sacchetti L, Genç E, Özer M, Pathare A, Krishnamoorthy R, Paldi A, Siguret V, Loriot MA, Kutala VK, Suarez-Kurtz G, Perini J, Denny JC, Ramirez AH, Mittal B, Rathore SS, Sagreiya H, Altman R, Shahin MHA, Khalifa SI, Limdi NA, Rivers C, Shendre A, Dillon C, Suriapranata IM, Zhou HH, Tan SL, Tatarunas V, Lesauskaite V, Zhang Y, Maitland-van der Zee AH, Verhoef TI, de Boer A, Taljaard M, Zambon CF, Pengo V, Zhang JE, Pirmohamed M, Johnson JA, Fava C.

Clin Pharmacol Ther. 2018 Dec 2. doi: 10.1002/cpt.1323. [Epub ahead of print]

PMID:
30506689
2.

Social media as a tool for assessing patient perspectives on quality of life in metastatic melanoma: a feasibility study.

Makady A, Kalf RRJ, Ryll B, Spurrier G, de Boer A, Hillege H, Klungel OH, Goettsch W; GetReal Workpackage 1.

Health Qual Life Outcomes. 2018 Nov 29;16(1):222. doi: 10.1186/s12955-018-1047-z.

3.

Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: a matched pair analysis.

Henricks LM, van Merendonk LN, Meulendijks D, Deenen MJ, Beijnen JH, de Boer A, Cats A, Schellens JHM.

Int J Cancer. 2018 Nov 28. doi: 10.1002/ijc.32022. [Epub ahead of print]

PMID:
30485432
4.

Barriers to and Facilitators of Implementing Programs for Return to Work (RTW) of Cancer Survivors in Four European Countries: A Qualitative Study.

Tamminga SJ, Braspenning AM, Haste A, Sharp L, Frings-Dresen MHW, de Boer AGEM.

J Occup Rehabil. 2018 Nov 22. doi: 10.1007/s10926-018-9818-2. [Epub ahead of print]

PMID:
30467648
5.

Differences in self-rated health and work ability between self-employed workers and employees: Results from a prospective cohort study in the Netherlands.

Sewdas R, Tamminga SJ, Boot CRL, van den Heuvel SG, de Boer AG, van der Beek AJ.

PLoS One. 2018 Nov 12;13(11):e0206618. doi: 10.1371/journal.pone.0206618. eCollection 2018.

6.

Longitudinal Associations Between Fatigue and Perceived Work Ability in Cancer Survivors.

Wolvers MDJ, Leensen MCJ, Groeneveld IF, Frings-Dresen MHW, De Boer AGEM.

J Occup Rehabil. 2018 Nov 7. doi: 10.1007/s10926-018-9814-6. [Epub ahead of print]

PMID:
30406343
7.

Trends in moderate and severe exacerbations among COPD patients in the UK from 2005 to 2013.

Oshagbemi OA, Keene SJ, Driessen JHM, Jordan R, Wouters EFM, de Boer A, de Vries F, Franssen FME.

Respir Med. 2018 Nov;144:1-6. doi: 10.1016/j.rmed.2018.09.010. Epub 2018 Sep 17.

PMID:
30366578
8.

Male and Female Partner-Caregivers' Burden: Does It Get Worse Over Time?

Swinkels JC, Broese van Groenou MI, de Boer A, Tilburg TGV.

Gerontologist. 2018 Oct 12. doi: 10.1093/geront/gny132. [Epub ahead of print]

PMID:
30321338
9.

Implementing managed entry agreements in practice: The Dutch reality check.

Makady A, van Veelen A, de Boer A, Hillege H, Klungel OH, Goettsch W.

Health Policy. 2018 Sep 28. pii: S0168-8510(18)30529-3. doi: 10.1016/j.healthpol.2018.09.016. [Epub ahead of print]

PMID:
30316540
10.

The Quality of Working Life Questionnaire for Cancer Survivors: Sufficient responsiveness for use as a patient-reported outcome measurement.

Tamminga SJ, de Jong M, Frings-Dresen MHW, de Boer AGEM.

Eur J Cancer Care (Engl). 2018 Nov;27(6):e12910. doi: 10.1111/ecc.12910. Epub 2018 Sep 4.

PMID:
30178900
11.

Use of proton pump inhibitors and risk of iron deficiency: a population-based case-control study.

Tran-Duy A, Connell NJ, Vanmolkot FH, Souverein PC, de Wit NJ, Stehouwer CDA, Hoes AW, de Vries F, de Boer A.

J Intern Med. 2018 Aug 23. doi: 10.1111/joim.12826. [Epub ahead of print]

PMID:
30141278
12.

Magnetic resonance imaging T1- and T2-mapping to assess renal structure and function: a systematic review and statement paper.

Wolf M, de Boer A, Sharma K, Boor P, Leiner T, Sunder-Plassmann G, Moser E, Caroli A, Jerome NP.

Nephrol Dial Transplant. 2018 Sep 1;33(suppl_2):ii41-ii50. doi: 10.1093/ndt/gfy198.

13.

Prognostic factors for return to work and work disability among colorectal cancer survivors; A systematic review.

den Bakker CM, Anema JR, Zaman AGNM, de Vet HCW, Sharp L, Angenete E, Allaix ME, Otten RHJ, Huirne JAF, Bonjer HJ, de Boer AGEM, Schaafsma FG.

PLoS One. 2018 Aug 15;13(8):e0200720. doi: 10.1371/journal.pone.0200720. eCollection 2018.

14.

Non-steroidal anti-inflammatory drugs and the risk of out-of-hospital cardiac arrest: a case-control study.

Bakhriansyah M, Souverein PC, Klungel OH, de Boer A, Blom MT, Tan HL.

Europace. 2018 Aug 10. doi: 10.1093/europace/euy180. [Epub ahead of print]

PMID:
30107407
15.

Employees Diagnosed with Cancer: Current Perspectives and Future Directions from an Employer's Point of View.

Tamminga SJ, Wolvers MDJ, Greidanus MA, Zaman AGNM, Braspenning AM, Frings-Dresen MHW, de Boer AGEM.

J Occup Rehabil. 2018 Jul 23. doi: 10.1007/s10926-018-9802-x. [Epub ahead of print]

PMID:
30039313
16.

Combined use of polypill components in patients with type 2 diabetes mellitus.

Janssen VE, Visseren FL, de Boer A, Grobbee DE, Westerink J, van der Graaf Y, Lafeber M; SMART Study Group.

Eur J Prev Cardiol. 2018 Sep;25(14):1523-1531. doi: 10.1177/2047487318789494. Epub 2018 Jul 23.

PMID:
30033753
17.

What Employer Actions Are Considered Most Important for the Return to Work of Employees with Cancer? A Delphi Study Among Employees and Employers.

Greidanus MA, Tamminga SJ, de Rijk AE, Frings-Dresen MHW, de Boer AGEM.

J Occup Rehabil. 2018 Jul 19. doi: 10.1007/s10926-018-9800-z. [Epub ahead of print]

PMID:
30027426
18.

Using a single noninferiority margin or preserved fraction for an entire pharmacological class was found to be inappropriate.

Althunian TA, de Boer A, Groenwold RHH, Klungel OH.

J Clin Epidemiol. 2018 Dec;104:15-23. doi: 10.1016/j.jclinepi.2018.07.004. Epub 2018 Aug 25.

PMID:
30009941
19.

Challenges for pulmonary delivery of high powder doses.

Sibum I, Hagedoorn P, de Boer AH, Frijlink HW, Grasmeijer F.

Int J Pharm. 2018 Sep 5;548(1):325-336. doi: 10.1016/j.ijpharm.2018.07.008. Epub 2018 Jul 2. Review.

20.

Work-Related Outcomes in Self-Employed Cancer Survivors: A European Multi-country Study.

Torp S, Paraponaris A, Van Hoof E, Lindbohm ML, Tamminga SJ, Alleaume C, Van Campenhout N, Sharp L, de Boer AGEM.

J Occup Rehabil. 2018 Jun 26. doi: 10.1007/s10926-018-9792-8. [Epub ahead of print]

PMID:
29946813

Supplemental Content

Loading ...
Support Center